SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

FDA Accepts uniQure Huntington’s Disease Therapy Application for Priority Review

The FDA set a May 1, 2027 PDUFA target action date for ifezuntirgene inilparvovec.

QURE
SquawkNews Desk 1 updates Updated Nov 02, 2026, 12:09 PM UTC

Story updates

12:09:27 PM UTC
SquawkNews
~ FDA sets PDUFA target action date of May 1, 2027 ~~ If approved, ifezuntirgene inilparvovec will be the world’s first disease-modifying treatmentfor Huntington’s disease ~LEXINGTON, Mass. and AMSTERDAM, Nov. 02, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. NASDAQ:QURE, a leading gene therapy company adv…

Related stories

Hangzhou SDIC Microelectronics and Controlling Shareholder Probed by Regulator The company says it and its controlling shareholder are under investigation over suspected information disclosure violations. L impact | REGULATION | Nov 02, 2026, 01:41 PM UTC FDA Places Bright Minds Biosciences Seizure Drug Application on Partial Hold Bright Minds Biosciences said the FDA placed its drug application and planned trial for a seizure treatment on partial clinical hold following a review. The stock fell 36% to $35 i M impact | REGULATION | Nov 02, 2026, 01:19 PM UTC NRx Pharmaceuticals Receives FDA Approval for Preservative-Free Ketamine NRx Pharmaceuticals said the FDA approved its preservative-free ketamine application ahead of the agency’s November 10 goal date. M impact | REGULATION | Nov 02, 2026, 01:13 PM UTC UniQure Says FDA Accepts Application for Huntington’s Gene Therapy UniQure said the FDA accepted an application for its potential Huntington’s disease gene therapy. L impact | REGULATION | Nov 02, 2026, 01:06 PM UTC Catheter Precision Announces FDA 510(k) Clearance for VIVO System The clearance enables use of the VIVO system in a broader patient population. L impact | REGULATION | Nov 02, 2026, 01:05 PM UTC Lupin Receives U.S. FDA Approval for Amifampridine Tablets M impact | REGULATION | Nov 02, 2026, 12:34 PM UTC